Clinical Trials Finder
Independent ClinicalTrials.gov directory
ClinicalTrials.gov record
Recruiting Phase 1 Interventional

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

ClinicalTrials.gov ID: NCT04485013

Public ClinicalTrials.gov record NCT04485013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 4, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab, Cetuximab or FOLFIRI Plus Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies

Study identification

NCT ID
NCT04485013
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Tizona Therapeutics, Inc
Industry
Enrollment
240 participants

Conditions and interventions

Conditions

Interventions

  • FOLFIRI Drug
  • TTX-080 Drug
  • cetuximab Drug
  • pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 13, 2020
Primary completion
May 31, 2027
Completion
May 31, 2027
Last update posted
Feb 17, 2026

2020 – 2027

United States locations

U.S. sites
41
U.S. states
26
U.S. cities
40
Facility City State ZIP Site status
Arizona Oncology Associates Tucson Arizona 85711 Completed
University of Southern California Los Angeles California 90033 Completed
Hoag Memorial Hospital Newport Beach California 92663 Completed
Rocky Mountain Cancer Centers Denver Colorado 80218 Recruiting
Yale Cancer Center New Haven Connecticut 06511 Completed
Christiana Care Helen F. Graham Cancer Center Newark Delaware 19713 Completed
John Hopkins Kimmer Cancer Center Washington D.C. District of Columbia 20016 Completed
Florida Cancer Specialists Daytona Beach Florida 32117 Recruiting
Florida Cancer Specialists Fleming Island Florida 32003 Completed
Ocala Oncology Center Ocala Florida 34474 Recruiting
AdventHealth Research Institute Orlando Florida 32804 Completed
Illinois Cancer Specialists Arlington Heights Illinois 60005 Completed
University of Illinois Chicago Illinois 60612 Completed
Indiana University Indianapolis Indiana 46202 Completed
Norton Cancer Institute Louisville Kentucky 40241 Completed
American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders Bethesda Maryland 20817 Recruiting
Maryland Oncology Hematology Silver Spring Maryland 20904 Recruiting
Dana-Farber Cancer Institute Boston Massachusetts 02215 Completed
START Midwest Grand Rapids Michigan 49546 Recruiting
Regions Hospital Cancer Care Center Saint Paul Minnesota 55101 Recruiting
Washington University in St Louis St Louis Missouri 63110 Completed
Nebraska Cancer Center Oncology Hematology West P.C. Omaha Nebraska 68130 Recruiting
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 Recruiting
Icahn School of Medicine at Mount Sinai New York New York 10029 Completed
Stony Brook University Stony Brook New York 11794 Completed
University of Cincinnati Cincinnati Ohio 45267 Recruiting
Zangmeister Cancer Center Columbus Ohio 43219 Completed
The University of Toledo Toledo Ohio 43606 Completed
University of Oklahoma Oklahoma City Oklahoma 73104 Recruiting
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 Completed
Medical University of South Carolina Charleston South Carolina 29425 Completed
Sarah Cannon Research Institute Nashville Tennessee 37203 Recruiting
Vanderbilt - Ingram Cancer Center Nashville Tennessee 37232 Completed
Texas Oncology - Dallas Dallas Texas 75246 Recruiting
START Dallas Fort Worth Texas 76104 Recruiting
The University of Texas MD Anderson Cancer Center Houston Texas 77030 Completed
Texas Oncology - Paris Paris Texas 75460 Recruiting
NEXT Oncology San Antonio Texas 78229 Completed
NEXT Oncology Virginia Fairfax Virginia 22031 Recruiting
Northwest Medical Specialties Tacoma Washington 98405 Completed
Northwest Cancer Specialists Vancouver Washington 98684 Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04485013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2026 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04485013 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →